Rep. Robert Bresnahan, Jr. Sells Agilent Technologies, Inc. (NYSE:A) Shares

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Agilent Technologies, Inc. (NYSE:A). In a filing disclosed on April 28th, the Representative disclosed that they had sold between $1,001 and $15,000 in Agilent Technologies stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Best Buy (NYSE:BBY) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of EOG Resources (NYSE:EOG) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of CSX (NASDAQ:CSX) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Valero Energy (NYSE:VLO) on 4/8/2025.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $107.46 on Wednesday. Agilent Technologies, Inc. has a 52-week low of $96.43 and a 52-week high of $155.35. The firm has a fifty day moving average of $115.21 and a 200-day moving average of $130.50. The firm has a market capitalization of $30.64 billion, a P/E ratio of 24.70, a PEG ratio of 3.01 and a beta of 1.19. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. As a group, analysts predict that Agilent Technologies, Inc. will post 5.54 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st were given a $0.248 dividend. This represents a $0.99 annualized dividend and a dividend yield of 0.92%. The ex-dividend date was Tuesday, April 1st. Agilent Technologies’s payout ratio is currently 22.76%.

Analysts Set New Price Targets

A has been the topic of a number of recent research reports. Barclays reduced their price target on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Jefferies Financial Group dropped their price objective on shares of Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a report on Monday, April 21st. Wells Fargo & Company dropped their price objective on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. TD Cowen increased their price objective on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a report on Thursday, April 10th. Finally, Robert W. Baird dropped their price objective on shares of Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Agilent Technologies currently has an average rating of “Moderate Buy” and an average price target of $143.00.

Institutional Trading of Agilent Technologies

Several large investors have recently made changes to their positions in the business. Sienna Gestion lifted its stake in Agilent Technologies by 29.8% in the fourth quarter. Sienna Gestion now owns 78,445 shares of the medical research company’s stock valued at $10,537,000 after buying an additional 17,991 shares during the period. Sequoia Financial Advisors LLC lifted its stake in Agilent Technologies by 8.5% in the fourth quarter. Sequoia Financial Advisors LLC now owns 33,898 shares of the medical research company’s stock valued at $4,554,000 after buying an additional 2,664 shares during the period. S.E.E.D. Planning Group LLC lifted its stake in Agilent Technologies by 12.7% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 42,587 shares of the medical research company’s stock valued at $5,721,000 after buying an additional 4,805 shares during the period. Prudential PLC lifted its stake in Agilent Technologies by 16.0% in the fourth quarter. Prudential PLC now owns 73,273 shares of the medical research company’s stock valued at $9,843,000 after buying an additional 10,128 shares during the period. Finally, Commonwealth Equity Services LLC lifted its stake in Agilent Technologies by 9.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company’s stock valued at $5,892,000 after buying an additional 3,915 shares during the period.

Insider Buying and Selling at Agilent Technologies

In other news, Director Daniel K. Podolsky sold 1,819 shares of the business’s stock in a transaction on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares of the company’s stock, valued at $4,161,931.02. The trade was a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total transaction of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.